Oral candidiasis of HIV-infected children undergoing sequential HIV therapies

Nadja R. Melo, Hideaki Taguchi, Vitoria P. Culhari, Katsuhiko Kamei, Yuzuru Mikami, Stephen N. Smith*, Marluce S. Vilela

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Candida oral flora from 52 Brazilian HIV-infected children was characterized while they received antiviral monotherapy therapy and subsequently, HAART with the use of protease inhibitor. There was a significant increase in non-C. albicans Candida isolates from 9.6-28.8% (P=0.005) after the children were placed on protease inhibitor therapy. Although Candida albicans still remained the most commonly isolated species, relative presence of C. tropicalis (n=9) followed by C. parapsilosis (n=8) markedly increased in association with protease inhibitor therapy. Furthermore, rare Candida species including C. dubliniensis, C. norvegensis, C. humicula and C. rugosa also appeared after the onset of protease inhibitor therapy. Subsequent investigation of the antifungal sensitivity of these diverse isolates, derived during protease inhibitor therapy, demonstrated some variation in antifungal sensitivity. With notable exceptions, the majority were sensitive to amphotericin B while most C. albicans and non-C. albicans Candida isolates were also susceptible to fluconazole, itraconazole and ketoconazole. Amongst exceptions was a single C. tropicalis isolates which was resistant to fluconazole (MIC>64 μl/ml) and one C. albicans-B isolate which showed cross-resistance to all azoles and amphotericin.

Original languageEnglish
Pages (from-to)149-156
Number of pages8
JournalMedical Mycology
Issue number2
Publication statusPublished - 1 Mar 2009


  • Candida
  • HIV
  • Pediatric


Dive into the research topics of 'Oral candidiasis of HIV-infected children undergoing sequential HIV therapies'. Together they form a unique fingerprint.

Cite this